Deal Note: Crowell & Moring Client Integrated BioTherapeutics Enters Into Exclusive Agreement with Chembio Diagnostics to Develop POC Diagnostic Tests for Ebola
Washington, D.C. – October 27, 2014: Crowell & Moring, LLP is representing Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases, as it enters into an exclusive agreement with Chembio Diagnostics, Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement. Financial terms of the agreement were not disclosed.
Contact(s):
Phill McGowan
Director of PR, Media and Communication
+1 202.508.8835
Email: pmcgowan@crowell.com